IPSEN (IPSEY) Expected to Release Earnings on Thursday

IPSEN (OTCMKTS:IPSEY) is projected to issue its resultson Thursday, July 30th. Analysts expect IPSEN to announce earnings of $1.86 per share and revenue of $2.4202 billion for the quarter.

IPSEN Price Performance

Shares of OTCMKTS:IPSEY opened at $47.11 on Thursday. IPSEN has a 12-month low of $30.05 and a 12-month high of $51.10. The business has a 50-day moving average price of $46.32 and a 200 day moving average price of $45.08.

Analyst Ratings Changes

IPSEY has been the topic of several recent research reports. HC Wainwright reissued a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th. Zacks Research upgraded shares of IPSEN to a “hold” rating in a research report on Friday, May 29th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a report on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold”.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).